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Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are both common 
causes of breathlessness and often conspire to confound accurate diagnosis and optimal 
therapy. Risk factors (such as aging, smoking and obesity) and clinical presentation (for 
instance, cough and breathlessness on exertion) can be very similar, but the treatment and 
prognostic implications are very different. In this review, we discuss the diagnostic 
challenges in individuals with exertional dyspnoea. We also highlight the prevalence, clinical 
relevance and therapeutic implications of a concurrent diagnosis of COPD and heart failure.  
 




 COPD and heart failure are both common and share many risk factors  
 Heart failure and COPD frequently co-exist and such patients have a poor prognosis 
 Determining whether breathlessness is due predominantly to lung or heart disease can 
be difficult; missed diagnoses are common  
 The combined effect of treatments for HFrEF on outcome is large and therefore the 
diagnosis should not be missed 
 COPD may deter the introduction or dose of beta-blockers, a key treatment for HFrEF 
 Treatments do not substantially alter outcomes for COPD or HFpEF 
 
Introduction 
Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are increasingly 
common and often co-exist. Together they probably cause or complicate about 10% of all 
hospital admissions. However, perhaps fewer than half of patients who have these conditions 
have appropriate investigation and diagnosis. Furthermore, the diagnosis of one condition 
may obscure the presence of the other (1, 2). HF and COPD have much in common, 
including risk factors (for instance, a lifelong history of smoking and obesity), symptoms 
(breathlessness and cough) and clinical signs (lung crackles and peripheral oedema). 
Differentiating between the two conditions is a diagnostic challenge, but their correct 
identification is essential: the correct treatment will improve the long-term outcome of many 
patients with heart failure, whereas there is little treatment that has a profound impact on 
outcome for COPD (3, 4). 
In this review, we will discuss the diagnostic challenges in distinguishing COPD from 
chronic heart failure in patients with exertional dyspnoea. We will also discuss the 
prevalence, clinical relevance and therapeutic implications associated with a concurrent 
diagnosis of COPD and heart failure. 
 
COPD and heart failure: a diagnostic challenge 
 









With rare exceptions (such as constrictive pericarditis), when intra-cardiac pressures rise or 
renal water and salt retention occur leading to fluid overload, the heart produces natriuretic 
peptides (NPs) as a counter-regulatory strategy designed to cause natriuresis and vasodilation.  
Increasing plasma concentrations of NPs are the single most powerful predictor of adverse 
outcome in patients with heart failure, regardless of left ventricular ejection fraction (17, 18). 
A normal plasma concentration of NPs rules out serious cardiac dysfunction (in constrictive 
pericarditis, plasma concentrations of NPs are lower than expected from the clinical picture 
but rarely normal). The diagnostic utility of NPs is currently recognised by all international 
guidelines on heart failure, including the National Institute for Health and Care Excellence 
and the European Society for Cardiology, to rule out important cardiac dysfunction in 
patients with suspected HF, acute or chronic (3). 
 
Screening studies suggest that up to 50% of patients with COPD have increased plasma 
concentrations of NPs, although no large definitive study exists (table 1)19-22. Raised plasma 
NPs in patients with COPD predict a higher mortality, whether or not they have received a 
diagnosis of HF (23, 24). For patients with COPD, increased plasma concentrations of high-
sensitivity troponin-I, suggesting ongoing myocardial damage, are also associated with high 
rates of CV events, but not with exacerbations of COPD (25). No blood biomarkers are 
currently recommended for the identification of people with COPD.  Patients with an 




Cardiac imaging (most commonly echocardiography) is an essential investigation for 
breathless patients who have an elevated plasma NP or in whom a cardiac contribution to 
breathlessness is suspected or needs to be excluded. It is important not to miss patients with a 
reduced left ventricular ejection fraction or severe valve disease, for which highly effective 
treatments exist. If these abnormalities are excluded, a dilated left atrium implies that the 
patient has abnormal left ventricular diastolic function and suggests the diagnosis of HFpEF. 
An echocardiogram should be considered in patients with an exacerbation of COPD, as 
around 25% of patients will have an important, potentially treatable, underlying heart 
problem (26, 27).   
 
How common are COPD and heart failure? 
“getting older” or “being unfit ”
COPD, whilst the prevalence of heart 
failure is perhaps 1-2%. Many reports suggest that a large proportion of breathlessness 
patients have both conditions (tables 226, 29-36 and 337-48). It’s worth noting that the diagnosis 
of “heart failure” includes those with either a reduced (HFrEF) or preserved (HFpEF) left 
ventricular ejection fraction on imaging, which have a similar prevalence. 
 
In surveys of COPD, heart failure is espite 
the high prevalence of ischaemic heart disease, smoking, and echocardiographic 
abnormalities in patients with COPD, COPD itself is, surprisingly, not strongly associated 
with heart failure in epidemiological studies. Perhaps once a diagnosis of COPD is made, 
clinicians do not look for other problems to explain symptoms. However, missing a diagnosis 
of 
Prevalence and prognostic relevance of COPD in people with HF
The prevalence of COPD amongst patients with HF ranges from 10-20% in large trials and 
registries where COPD was either self-reported by patients or based on the opinion (non-
standardized) of researchers (table 3). In smaller studies that used lung function tests to 
evaluate airflow obstruction objectively, up to 50% of patients with HF have abnormal 
spirometry. This wide discrepancy might suggest that the diagnosis of COPD is often missed, 
perhaps because cardiologists pay little attention to airway disease in the presence of a more 
deadly, but treatable, condition. However, it is also possible that HF has effects on the lung 
that mimic the effects of COPD leading to over-diagnosis. Interstitial lung oedema can 
compress alveoli and distal airways; cardiomegaly or pleural effusion can reduce the intra-
thoracic space and compress lung volumes; decreased respiratory muscle strength can reduce 
inspiratory and expiratory forces; frailty may impair the ability to perform spirometry 
accurately and normal values in those aged >80 years of age are not well-defined, which 
might lead to over-diagnosis by spirometry (49). Moreover, effective 
and reduce hospitalisations for respiratory infection (50, 51). 
Interpreting spirometric data in a patient with poorly controlled heart failure can be difficult.
factors (such as a 
lower use of HF medications in patients with concurrent COPD and HFrEF) is not clear (53-
55). 
 
Therapeutic concerns  
Beta-blockers improve the long-term prognosis of patients with HF due to left ventricular 
systolic dysfunction (3, 56). However, concerns about the potential for beta-blockers to cause 
bronchoconstriction and block the effect of sympathomimetic bronchodilators dissuades 
many from giving these agents in adequate doses, if at all, to patients with concomitant heart 
failure and COPD (table 3). However, the available clinical evidence suggests that these fears 
are unfounded. Small randomised trials show that any decline in FEV1 associated with beta-
blockers does not translate into worsening symptoms or quality of life in patients with HF 
and COPD (57, 58).  The use of a cardio selective beta-blocker, such as bisoprolol or 
nebivolol, might be preferred, at least theoretically, when there is concern about tolerability 
(59, 60).  
 
Perhaps surprisingly, there is accumulating evidence from observational studies and sub-
analyses from randomised trials conducted in patients with COPD which suggest that a 
higher heart rate is associated with an increase in mortality, and that beta-blockers might 
reduce exacerbations of COPD and prolong survival (61-63). Some of this apparent benefit 
might reflect inadvertent, “accidental” treatment of undiagnosed heart failure. A multicenter, 
prospective, randomized, double-blind, placebo-controlled trial is currently ongoing to test 
whether metoprolol reduces time to first exacerbation of COPD and of cardiovascular events 
in patients with moderate to severe COPD (ClinicalTrials.gov Identifier: NCT02587351) 
(64).    
 
There is no evidence that treatment for COPD improves long-term survival substantially. 
Beta-agonists can improve lung function tests in patients with COPD, but they might worsen 
cardiovascular and HF outcomes, especially for patients with HFrEF who are not protected 
by beta-blockers (65-67). Inhaled steroids may increase the risk of pneumonia (68). Oral 
steroids may increase sodium and water retention (69). Certainly, a large proportion of 
patients with COPD can tolerate de-escalation of respiratory therapies, particularly those at 
low risk of exacerbations. Attempts to identify patients in whom treatments for COPD can be 
discontinued should be encouraged (70, 71).       
 
Conclusions 
Neither COPD nor HF has a robust definition, creating uncertainty about the true prevalence 
of either condition. Missed diagnoses are common especially when one or other condition 
provides a seemingly adequate explanation for a patient’s symptoms. However, there is no 
doubt that these two conditions commonly co-exist. 
For patients with COPD, no specific treatment improves survival but they have high rates of 
cardiovascular events, and often die of the consequences. Greater focus on cardiovascular 
rather than respiratory disease in patients with COPD might improve outcomes. However, 
there is no doubt that appropriate treatment reduces the morbidity and mortality of patients 
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